A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas Read more
Outcomes of Current Front-Line Therapy Regimens in Elderly Patients with Classical Hodgkin’s Lymphoma Read more
Retrospective Analysis of intensive chemotherapy (modified Hyper-CVAD) in aggressive Non-Hodgkin Lymphoma patients – CNS outcomes Read more
Examining COVID19 course and outcomes in patients previously diagnosed with chronic lymphocytic leukemia (CLL) Read more
Molecular Profiling of Diffuse Large B Cell Lymphoma and Acute Leukemias Treated with Dose Intense Regimens Read more
Outcomes of Anti-CD19 Chimeric Antigen Receptor (CAR) T-cell Patients: Real World Experience in Lymphoma Patients Read more
Effect of Adding Venetoclax to Intensive Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia Read more
Genotypic signatures of response to Venetoclax and Hypomethylating agent in treatment naive Acute Myeloid Leukemia and Myelodysplastic Syndrome Read more
